AVXL
Fiscal year ends September Quarters are offset from the calendar — Q1 is Oct–Dec

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing oral therapies for neurodegenerative and neurodevelopmental diseases. The company focuses on central nervous system disorders with high unmet need, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, and Fragile X syndrome. Its primary pipeline asset is ANAVEX®2-73 (blarcamesine), an oral therapy that activates the sigma-1 receptor (SIGMAR1) to restore cellular homeostasis and boost autophagy. ANAVEX®2-73 is being evaluated in clinical trials for early Alzheimer’s disease, as well as for rare pediatric conditions like Rett syndrome and Fragile X syndrome. The company also has ANAVEX®3-71 in clinical development and other compounds in pre-clinical stages. Anavex utilizes precision medicine approaches, analyzing genomic data from clinical trials to identify biomarkers that predict patient response to its therapies. The company collaborates with academic institutions, such as Stanford University, for quantitative imaging studies to validate target engagement. Its development strategy emphasizes oral formulations designed to improve brain health by addressing underlying biological mechanisms of disease progression.

Summarised from the company's own disclosures, fiscal year ended Nov 2025

Industry Biotechnology Homepage anavex.com
Sector Healthcare IR page anavex.com/investors
Tags
neurodegenerative diseases, neurodevelopmental disorders, alzheimer's disease, parkinson's disease, rett syndrome, fragile x syndrome, sigma-1 receptor agonists, precision medicine, clinical-stage, oral therapeutics, ANAVEX®2-73, blarcamesine, ANAVEX®3-71, ANAVEX19-144
Press page anavex.com/news

Metrics

Valuation  
Market cap $ 187.248M
Market cap (USD) $ 187.248M
P/E -13.47
PEG —
P/BV 1.67
P/S —
P/OCF -6.39
P/FCF -4.80
Dividend yield —
Turnover / mcap —
Returns  
ROE -43.1%
ROI -48.9%
ROIC -40.6%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 10
Quality score -76.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Assets 103.815M 135.567M 154.386M 152.705M 161.616M 34.542M 25.329M 24.376M 27.838M 9.499M 15.47M 7.354M 393.449K 13.153K 203.039K 329.849K — —
Net profit -46.377M -43.002M -47.505M -47.978M -37.909M -26.28M -26.295M -17.453M -13.46M -14.737M -12.108M -11.368M -3.7M -8.302M -7.307M -8.783M — —
Free cash flow -39.044M -30.812M -27.785M -24.238M — — — — — — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Share price 8.9 5.68 6.55 10.32 17.95 4.55 3.16 2.73 4.14 3.63 0.52 0.17 0.62 1.05 2.83 2.25 2.25 1.7
Price performance 12m 0.57 -0.13 -0.37 -0.43 2.95 0.44 0.16 -0.34 0.14 5.98 2 -0.72 -0.41 -0.63 0.26 0 0.32 -0.53

Filed figures

Figure Sep 2016 Sep 2017 Sep 2018 Sep 2019 Sep 2020 Sep 2021 Sep 2022 Sep 2023 Sep 2024 Sep 2025
Balance sheet detail
Cash and deposits (USD) 9.19M 27.4M 22.9M 22.2M 29.2M 152M 149M 151M 132M 103M
Cash flow detail
Operating cash flow (USD) -9.24M -9.02M -12.6M -18.5M -21.3M -30.4M -24.2M -27.8M -30.8M -39M
Change in receivables (cash effect) (USD) -2,507 54,435 -30,423 — — — — — — —
Change in payables (cash effect) (USD) 775,332 554,709 300,292 683,797 465,722 750,727 -915,004 497,000 5.31M -5.38M
Share-based compensation (USD) 5.06M 4.14M 5.52M 6.43M 4.88M 8.23M 18.4M 16.4M 9.44M 11.5M
Operating cash flow before change in receivables (USD) -9.23M -9.07M -12.6M — — — — — — —
Income detail
Research and development expense (USD) 7.25M 10.7M 13.3M 22.3M 25.2M 33M 37.9M 43.7M 41.8M 37.6M
↳ 5y CAGR +22.8% +32.1% +119.2% +98.0% +61.9% +35.4% +28.9% +26.8% +13.5% +8.3%
Reported Dec 12, 2018 Dec 12, 2018 Dec 12, 2018 Dec 16, 2019 Dec 28, 2020 Nov 24, 2021 Nov 28, 2022 Nov 27, 2023 Dec 23, 2024 Nov 25, 2025

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Seasoned biopharmaceutical executive with more than 30 years of leadership experience spanning clinical development, regulatory strategy and operational execution appointed to lead company into new phase of clinical development and growth

NEW YORK, November 3, 2026 – Anavex Life Sciences Corp. (Nasdaq: AVXL) (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system diseases with significant unmet medical needs, today announced that on November 1, 2026, its Board of Directors appointed Terrie Kellmeyer, Ph.D., who had been serving as the Company’s Interim Chief Executive Officer, as the Company’s President and Chief Executive Officer. She will also join Anavex’s Board of Directors.

“Dr. Kellmeyer has provided steady leadership and a clear vision during an important period for Anavex, sharpening the focus of our clinical programs and advancing our engagement with the FDA,” said Peter Donhauser, D.O., member of the Board of Directors. “She brings a deep understanding of our science, a disciplined approach to execution and an unwavering commitment to patients.

On October 28, 2026, each of Dr. Jiong Ma, Mr. Gautam Patel and Dr. Adrian Senderowicz resigned from the Board of Directors (“Board”) of Anavex Life Sciences Corp. (“Anavex” or the “Company”) effective as of October 28, 2026. Prior to such resignations, Dr. Ma served as the Chair of the Board and a member of the Audit Committee of the Board, Mr. Patel served as a member of the Audit Committee of the Board and Dr. Senderowicz was not serving on any Board committees.

As stated in Dr. Ma’s resignation letter, Dr. Ma has decided that her views about the Company’s strategic direction are not fully aligned with those of the Board and management.

As stated in Mr. Patel’s resignation letter, Mr. Patel has concluded that his personal views regarding the Company’s strategy to execute its business plan do not sufficiently align with those of the Board and management.

As stated in Dr. Senderowicz’s resignation letter, Dr. Senderowicz has concluded that his personal views regarding the Company’s strategy to execute its business plan do not sufficiently align with those of the Board and management.

The descriptions of the resignation letters of Dr. Ma, Mr. Patel and Dr.

October 20, 2026

Clinical conduct of both blarcamesine (ANAVEX®2-73) studies in healthy volunteers is now complete, data are expected to support clinical pharmacology characterization across pipeline programs

NEW YORK, NY, October 20, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system diseases with significant unmet medical needs, today provided a corporate update highlighting progress across its three core indications for blarcamesine (ANAVEX 2-73): early Alzheimer’s disease, Rett syndrome and Fragile X syndrome. Recent Company highlights include the completion of clinical conduct of the Drug-drug Interaction (DDI) and Absorption, Distribution, Metabolism and Excretion (ADME) studies of blarcamesine, clearance by the U.S. Food and Drug Administration (FDA) of the Company’s Investigational New Drug (IND) application in Fragile X syndrome, and an upcoming meeting with the FDA in November to discuss adding pediatric participants to the Phase 3 Rett syndrome study.

“Completion of the DDI and ADME studies represents an important milestone for blarcamesine, advancing the clinical pharmacology data package recommended by the FDA, which we expect to benefit our ongoing core programs.” said Terrie Kellmeyer, Ph.D., Interim Chief Executive Officer. “Together with the FDA’s recent clearance of our IND in Fragile X syndrome, these studies reflect positive progress and execution on timelines previously set forth. With these achievements, we believe that we are well positioned to continue to move forward on our strategic objectives through the remainder of the year.”

Alzheimer’s Disease Program

Anavex has completed clinical conduct of two clinical pharmacology studies of blarcamesine. The studies address clinical pharmacology data recommended by the FDA and the data are expected to support the Company’s FDA-focused development program. The FDA’s recommendation is aligned with feedback the Company received from the European Medicines Agency (EMA).

  • DDI study: The last participant completed the study at the end of September, concluding clinical conduct.

  • The study was fully enrolled with 65 participants, all of whom received 30 mg of blarcamesine. Based on preliminary observations, no serious adverse events were reported. Full safety and pharmacokinetic data analysis is ongoing.

  • ADME study: The last participant completed the study in mid-October, concluding clinical conduct.

  • The study enrolled 8 participants, all of whom received 30 mg of blarcamesine. Based on preliminary observations, no serious adverse events were reported. Full safety and pharmacokinetic data analysis is ongoing.

  • Both studies enrolled healthy volunteers and were designed to further characterize blarcamesine’s clinical pharmacology profile. Their data are critical for the Alzheimer’s disease program and are also expected to support development in the Company’s Rett syndrome and Fragile X syndrome programs.

Rett Syndrome Program

  • The Company has an FDA-aligned protocol for its Phase 3 study of blarcamesine in Rett syndrome in adult participants (ANAVEX2-73-RS-005). As previously announced on September 9, 2026, the FDA granted the Company a meeting to discuss adding pediatric participants to the Phase 3 protocol for November. Blarcamesine for the treatment of Rett syndrome has been granted Orphan Drug Designation by the FDA. The program remains on track with study start-up activities underway.

Fragile X Syndrome Program

  • The Company submitted an (IND application for blarcamesine in Fragile X syndrome in September 2026, and, as previously announced on October 15, 2026, the FDA has cleared the IND. Blarcamesine for the treatment of Fragile X syndrome has been granted Orphan Drug Designation by the FDA. Study start-up activities are underway.

Prompts

Anavex Life Sciences Corp. (ticker AVXL), listed in United States.

Company History

Date Change Detail
Feb 1, 2007 Renamed Thrifty Printing Inc. → ANAVEX LIFE SCIENCES CORP.

ETFs Holding Anavex Life Sciences Corp.

ETF Weight in ETF Shares Market value As of
RESM 0.01% 105 $ 271.95 Jun 30, 2026
DFAC 0.00% 26,068 $ 25.792K Nov 12, 2026
AVSC 0.00% 7,435 $ 6,078.86 Nov 16, 2026